Drugs / Ad26.CS.01
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01397227 | Jun 2011 → May 2012 | malaria | Crucell Holland BV | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad26.CS.01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01397227 ↗ |
| Route | Other | “Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).” NCT01397227 ↗ |